Vaccines: past, present and future

被引:352
作者
Plotkin, SA [1 ]
机构
[1] Univ Penn, Doylestown, PA 18901 USA
关键词
D O I
10.1038/nm1209
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines.
引用
收藏
页码:S5 / S11
页数:7
相关论文
共 87 条
[31]   A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis [J].
Horwitz, MA ;
Harth, G .
INFECTION AND IMMUNITY, 2003, 71 (04) :1672-1679
[32]   Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: Implications for assembly and vaccine production [J].
Huang, Y ;
Yang, ZY ;
Kong, WP ;
Nabel, GJ .
JOURNAL OF VIROLOGY, 2004, 78 (22) :12557-12565
[33]   A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity [J].
Jones, T ;
Allard, F ;
Cyr, SL ;
Tran, SP ;
Plante, M ;
Gauthier, J ;
Bellerose, N ;
Lowell, GH ;
Burt, DS .
VACCINE, 2003, 21 (25-26) :3706-3712
[34]   Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model [J].
Kantak, KN ;
Collins, SL ;
Lipman, EG ;
Bond, J ;
Giovanoni, K ;
Fox, BS .
PSYCHOPHARMACOLOGY, 2000, 148 (03) :251-262
[36]   Immunotherapeutic uses of CpG oligodeoxynucleotides [J].
Klinman, DM .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (04) :248-257
[37]   A controlled trial of a human papillomavirus type 16 vaccine [J].
Koutsky, LA ;
Ault, KA ;
Wheeler, CM ;
Brown, DR ;
Barr, E ;
Alvarez, FB ;
Chiacchierini, LM ;
Jansen, KU .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1645-1651
[38]   Can successful vaccines teach us how to induce efficient protective immune responses? [J].
Lambert, PH ;
Liu, M ;
Siegrist, CA .
NATURE MEDICINE, 2005, 11 (04) :S54-S62
[39]   Decline in Varicella-Zoster Virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine [J].
Levin, MJ ;
Smith, JG ;
Kaufhold, RM ;
Barber, D ;
Hayward, AR ;
Chan, CY ;
Chan, ISF ;
Li, DJJ ;
Wang, W ;
Keller, PM ;
Shaw, A ;
Silber, JL ;
Schlienger, K ;
Chalikonda, I ;
Vessey, SJR ;
Caulfield, MJ .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (09) :1336-1344
[40]   Therapeutic cancer vaccines: Using unique antigens [J].
Lewis, JJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14653-14656